Specific Reveal 系统对革兰阴性菌阳性血培养瓶快速药敏试验的性能评估
该研究评估了 Reveal 快速药敏系统直接从革兰阴性菌阳性血培养瓶进行药敏试验的性能。共纳入 102 瓶阳性血培养瓶,与 DxM MicroScan WalkAway 对比,基本一致率(EA)为 98.5%,分类一致率(CA)为 97.1%;对 10 株高耐药菌株的 EA 为 99.6%,CA 为 97.9%。Reveal 平均报告时间为 5.4 h ± 1.2 h,显著短于常规方法的 16 h。
要点
- Reveal 系统直接从阳性血培养瓶进行药敏试验,与常规方法一致性高。
- 对常见菌-药组合,Reveal 系统满足欧洲 ISO 药敏系统性能指南。
- Reveal 系统无需传代培养,平均报告时间仅 5.4 h,显著缩短周转时间。
核心结论
- Reveal 快速药敏系统直接从革兰阴性菌阳性血培养瓶进行药敏测定,对常见菌-药组合可靠准确,满足欧洲 ISO 药敏系统性能指南,且相比常规药敏显著缩短报告时间。
研究设计与样本
- 2021 年 2 月至 4 月纳入 102 瓶革兰阴性菌血症患者的阳性血培养瓶,所有分离株用 Reveal 系统直接检测,并与 DxM MicroScan WalkAway 对比。
- 另对 10 株高耐药 CDC & FDA AR 菌株进行双份药敏测试。
主要发现
- 临床菌株:Reveal 与 DxM MicroScan WalkAway 的基本一致率(EA)为 98.5%,分类一致率(CA)为 97.1%。
- 高耐药 CDC & FDA AR 菌株:EA 为 99.6%,CA 为 97.9%。
- Reveal 平均报告时间:临床菌株 5.4 h ± 1.2 h,高耐药 CDC & FDA AR 菌株 3.8 h ± 1.2 h;DxM MicroScan WalkAway 临床菌株平均 16 h。
关键数值与推荐
- 临床菌株 EA 98.5%、CA 97.1%;高耐药 CDC & FDA AR 菌株 EA 99.6%、CA 97.9%。
- Reveal 平均报告时间 5.4 h ± 1.2 h(临床菌株)和 3.8 h ± 1.2 h(高耐药 CDC & FDA AR 菌株)。
- Reveal 系统满足欧洲 ISO 药敏系统性能指南。
临床怎么用
- 对于革兰阴性菌阳性血培养瓶,可直接使用 Reveal 系统进行快速药敏试验,无需传代培养,缩短报告时间。
- 常见菌-药组合的药敏结果可靠,可辅助临床尽早启动适当抗菌治疗。
局限性
- 研究仅纳入 102 瓶阳性血培养瓶和 10 株高耐药参考菌株,样本量有限。
- 评估对象为革兰阴性菌,未涵盖其他病原体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rapid antimicrobial drug administration is crucial for the efficient treatment of sepsis or septic shock, but empirical therapy is limited by the increasing prevalence of multidrug-resistant bacteria. Thus, rapid and reliable antimicrobial susceptibility testing (AST) is needed to start appropriate antimicrobial drug administration as quickly as possible. In the present study, we evaluated the performance of the Reveal rapid AST system. From February to April 2021, 102 positive blood culture bottles (BCBs) from hospitalized patients with bacteremia caused by Gram-negative bacteria were included in the study. All isolates were tested by the Reveal system directly from the positive BCBs in comparison to the DxM MicroScan WalkAway. Essential agreement (EA) and category agreement (CA) were high with 98.5% and 97.1%, respectively. We also determined the susceptibility of 10 highly resistant CDC & FDA AR strains in duplicate. Here, EA was 99.6% and CA 97.9%. The average time to result by Reveal was 5.4 h ± 1.2 h compared to an average of 16 h by DxM MicroScan WalkAway for clinical strains and 3.8 h ± 1.2 h for more resistant CDC & FDA AR strains. Susceptibility determination with the Reveal rapid AST system directly from positive BCBs is for the frequently represented bug-drug combinations a reliable and accurate approach, meeting the European ISO guideline for the performance of AST systems. Moreover, AST directly from blood cultures performed with the Reveal system saves time when compared to the conventional AST, as no subculturing is needed and time to result is very short.
引用
- Ostermann G, Körber-Irrgang B, Krüger A, et al. Performance evaluation of the Specific Reveal system for rapid antibiotic susceptibility testing from positive blood cultures containing Gram-negative pathogens. J Clin Microbiol. 2024. PMID: 39545740. doi:10.1128/jcm.00692-24
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。